Current and future management of chronic spontaneous urticaria and chronic inducible urticaria
Allergy and Asthma Proceedings · 2023
DOI: 10.2500/aap.2023.44.220093 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy and Asthma Proceedings, 2023. Verfasst von Toan T Do und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Chronic Urticaria, Histamine H1 Antagonists, Non-Sedating, Urticaria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 110 Literaturangaben.
Abstract (Originalsprache)
Background
Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy.
Objective
A review of the current literature of standard and novel therapeutics in the management of CU was conducted.
Methods
A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials.
Results
Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab.
Conclusion
Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon.
- Department of Pediatrics, Oregon Health and Science University, Portland, Oregon, and.
- Section of Allergy and Clinical Immunology, Oregon Health and Science University, Portland, Oregon.
Zitieren
APA
Do, T. T., Canty, E. A., & Joshi, S. R. (2023). Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. Allergy and Asthma Proceedings. https://doi.org/10.2500/aap.2023.44.220093
Vancouver
Do TT, Canty EA, Joshi SR. Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. Allergy and Asthma Proceedings. 2023. doi:10.2500/aap.2023.44.220093
BibTeX
@article{Do2023,
author = {Do, Toan T and Canty, Ethan A and Joshi, Shyam R},
title = {Current and future management of chronic spontaneous urticaria and chronic inducible urticaria},
journal = {Allergy and Asthma Proceedings},
year = {2023},
doi = {10.2500/aap.2023.44.220093}
}
EUVIMED